We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Novel Biomarkers Predict the Development of Incident Heart Failure

By LabMedica International staff writers
Posted on 30 Dec 2020
Print article
Image: The IMMAGE 800 protein chemistry analyzer (Photo courtesy of Beckman Coulter).
Image: The IMMAGE 800 protein chemistry analyzer (Photo courtesy of Beckman Coulter).
Heart failure (HF), caused by abnormal cardiac structure and function, represents the end stage of several cardiac diseases, and significantly worsens both quality of life and life expectancy with a five year survival rate of approximately 50%. Lifetime risk of the development of HF is 20% and overall prevalence 2%.

Natriuretic peptides and troponins have been used in clinical diagnosis and treatment of HF, and they also predict incident HF. Transition from current practice of treating HF to biomarker‐based precise medicine targeted to prevent HF requires investigation of multiple biomarkers reflective of pathophysiological pathways resulting in HF.

Clinical Medical Scientists from the University of Eastern Finland (Kuopio, Finland) and the Kuopio University Hospital (Kuopio, Finland) used a random selection of 10,106 men, aged from 45 to 73 years, participating in the Metabolic Syndrome in Men (METSIM) study, who at baseline did not have a diagnosis of incident heart failure. Blood samples for proton nuclear magnetic resonance (NMR) analysis, metabolic, inflammatory, and other biomarkers were taken.

Levels of plasma glucose, insulin, hemoglobin A1c (HbA1c), glomerular filtration rate and urinary albumin excretions rate were measured and a two hour oral glucose tolerance test (75 g of glucose) was performed. Serum concentrations of hs‐CRP were assayed using kinetic immunoturbidimetry (IMMAGE Immunochemistry System; Beckman Coulter, Fullerton, CA, USA) and plasma interleukin 1 receptor antagonist (IL‐1RA) using an enzyme‐linked immunosorbent assay (ELISA) (R&D Systems, Inc., Minneapolis, MN, USA). Plasma adiponectin was measured using an ELISA kit (Linco Research, St. Charles, MI, USA). Proton nuclear magnetic resonance analysis was performed at the same time from the baseline serum samples.

The scientists reported that elevated levels of inflammatory biomarkers and several biomarkers associated with heart metabolism, which were measured by NMR analysis, were associated with the development of incident heart failure in a follow-up that lasted for 8.8 years. These new biomarkers included adiponectin, high-sensitivity C-reactive protein, the chronic inflammation biomarker glycoprotein acetyls, the amino acids alanine and phenylalanine, as well as glycerol and pyruvate, which the heart muscle uses for energy. Fasting plasma glucose and insulin, HbA1c, and urinary albumin excretion rate were also associated with HF.

Johanna Kuusisto, MD a Professor of Cardiology and senior author of the study, said, “Incident heart failure is typically associated with changes in heart metabolism as well as with low-grade, chronic inflammation. Based on our study, these changes are present even years before any sign of heart failure.” The study was published on December 5, 2020 in the journal ESC Heart Failure.

Related Links:
University of Eastern Finland
Kuopio University Hospital
Beckman Coulter
R&D Systems
Linco Research


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.